Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al.
Blood (2022) Vol. 140, Iss. 12, pp. 1345-1377
Open Access | Times Cited: 1700

Showing 26-50 of 1700 citing articles:

SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia
Céline Moison, Deanne Gracias, Julie Schmitt, et al.
Science Advances (2024) Vol. 10, Iss. 12
Open Access | Times Cited: 15
Exosomal circ_0006896 promotes AML progression via interaction with HDAC1 and restriction of antitumor immunity
Can Can, Xinyu Yang, Hexiao Jia, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Menglin Li, Yimeng Li, Qingyuan Qu, et al.
Cancer Letters (2025), pp. 217460-217460
Closed Access | Times Cited: 2
Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
HemaSphere (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
Keri Maher, Danielle Shafer, Dale Schaar, et al.
Cancer Chemotherapy and Pharmacology (2025) Vol. 95, Iss. 1
Open Access | Times Cited: 1
TP53 Mutant Variant Allele Frequency and Cytogenetics Determine Prognostic Groups in MDS/AML for Transplantation
Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal‐Shamanna, et al.
Blood Advances (2025)
Open Access | Times Cited: 1
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Emmanuel Gyan, Mark D. Minden, Kohmei Kubo, et al.
Cancer (2025) Vol. 131, Iss. 4
Open Access | Times Cited: 1
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Sophie Le Grand, Juliette Villemonteix, Étienne Daguindau, et al.
HemaSphere (2025) Vol. 9, Iss. 2
Open Access | Times Cited: 1
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
Brynn Levy, Linda B. Baughn, Yassmine Akkari, et al.
Blood Advances (2022) Vol. 7, Iss. 7, pp. 1297-1307
Open Access | Times Cited: 59
Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology
Ryan J. Stubbins, Annabel Francis, Florian Kuchenbauer, et al.
Current Oncology (2022) Vol. 29, Iss. 9, pp. 6245-6259
Open Access | Times Cited: 58
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
Curtis A. Lachowiez, Nicola Long, Jennifer N. Saultz, et al.
Blood Advances (2022) Vol. 7, Iss. 9, pp. 1899-1909
Open Access | Times Cited: 52
The present and future of measurable residual disease testing in acute myeloid leukemia
James S. Blachly, Roland B. Walter, Christopher S. Hourigan
Haematologica (2022) Vol. 107, Iss. 12, pp. 2810-2822
Open Access | Times Cited: 40
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1871-1891.e6
Open Access | Times Cited: 39
How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan
Blood (2023)
Open Access | Times Cited: 36
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
Jayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Blood (2023) Vol. 142, Iss. 19, pp. 1647-1657
Closed Access | Times Cited: 35
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 2, pp. 193-202
Open Access | Times Cited: 35
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
Brunangelo Falini, Maria Paola Martelli
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 481-492
Closed Access | Times Cited: 34
A review of treatment options employed in relapsed/refractory AML
Mohamed Zakee Mohamed Jiffry, Robert Kloss, Mohammad Ahmed-Khan, et al.
Hematology (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 31
How I treat refractory and relapsed acute myeloid leukemia
Felicitas Thol, Hartmut Döhner, Arnold Ganser
Blood (2023) Vol. 143, Iss. 1, pp. 11-20
Closed Access | Times Cited: 31
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 26, pp. 4236-4246
Open Access | Times Cited: 29
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing Soo Tiong, Jenny O’Nions, et al.
Blood (2023) Vol. 143, Iss. 4, pp. 336-341
Open Access | Times Cited: 29
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Álex Bataller, Alexandre Bazinet, Courtney D. DiNardo, et al.
Blood Advances (2023) Vol. 8, Iss. 4, pp. 927-935
Open Access | Times Cited: 29
Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26
Claire C. Homan, Hamish S. Scott, Anna Brown
Blood (2023) Vol. 141, Iss. 13, pp. 1533-1543
Open Access | Times Cited: 28
NPM 1 Mutations in AML—The Landscape in 2023
Naman Sharma, Jane L. Liesveld
Cancers (2023) Vol. 15, Iss. 4, pp. 1177-1177
Open Access | Times Cited: 26
Optical Genome Mapping for Cytogenetic Diagnostics in AML
Verena Nilius‐Eliliwi, Wanda M. Gerding, Roland Schroers, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1684-1684
Open Access | Times Cited: 25

Scroll to top